What We Do
Prevent Duplicate and Professional Subjects From Enrolling In Your Clinical Trials
Verified Clinical Trials helps sponsors and research sites detect and prevent poor quality professional or duplicate subjects from entering their clinical trials at the time of screening. And, the protections continue the entire duration of the study. Duplicate or professional research subjects result in failed clinical trials. VCT also detects and prevents 17 other important potential protocol violations. The protections continue the entire duration of the study. The verification is instantaneous and informative.
Reduce Placebo Rates and Improve Data Integrity
Insurance Policy For Your Clinical Trial
VCT detects poor quality ineligible subjects at the time of screening and the protections continue throughout the entire duration of the clinical trials.
Improve Study Data and Trial Outcomes
Verifying study subjects through Verified Clinical Trials’ processes helps to ensure high quality, and more accurate data collection while also protecting the safety of clinical trial volunteers. The VCT verification process is simple, yet thorough, and helps to promote the overall mission of clinical trials… to ultimately deliver safe and effective drugs to the market.
Without Verified Clinical Trials, study data accuracy and subject data is at risk. Poor quality or duplicate subjects oftentimes provide information that they believe will help keep them in the study. The professional subject will tell the research coordinator that they are feeling better or doing better. When in fact, these subjects are in the placebo arm, it raises the placebo rate and thereby causes issues with separation from placebo.
Alternatively, if the research subject is on the placebo or low-dose arm and then travels to multiple sites within the clinical trial and is indeed taking the study medication at numerous sites within the same trail, this also raises a placebo rate or causes faulty data. When research subjects participate in numerous clinical trials and combine multiple investigational products, this may result in increased adverse events.